LeonaBio

LeonaBio Dividend Yield

Dividend Yield of LeonaBio (LONA) as of Oct 22, 2026.

Dividend Yield

-

Last updated:

Dividend Yield of LeonaBio is 2026 - . Dividend Yield of LeonaBio was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LeonaBio Stock analysis

What does LeonaBio do? Athira Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington, that generates revenue by developing small molecules to restore neuronal health and stop neurodegeneration. The firm utilizes its proprietary ATH platform to target and enhance the activity of a vital neuronal growth factor, creating a pipeline of drugs designed to cross the blood brain barrier for the central nervous system or target the peripheral nervous system. This technology underpins the development of ATH-1017, which is specifically intended for the treatment of neurodegenerative disorders with an initial focus on Alzheimer’s disease. The product aims to improve symptoms in cognitively impaired subjects by enhancing neuronal health and promoting regeneration, serving the medical needs of patients suffering from these conditions. LeonaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LeonaBio stock

On Eulerpool you can find the complete historical development of Dividend Yield LeonaBio since 2006 – with annual values, charts, and detailed analysis.

Dividend yield measures the annual dividend payment relative to the stock price. It shows the return an investor receives from dividends alone.

Dividend Yield's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Yield's LeonaBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — LeonaBio

All Key Metrics — LeonaBio